Medical/Pharmaceuticals
C-Ray Therapeutics Supports Mednovo's Phase III Clinical Trial with First Patient Dosed for Lutetium [177Lu] Oxodotreotide Injection
CHENGDU, China, Sept. 10, 2025 /PRNewswire/ -- August 22, 2025, Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodotreotide Injection, a Class 3 targeted radiotherapeutic drug. As the exclusive...
2025-09-10 21:30
1288
Imaging Endpoints Announces Patent Application for AI Review Charter System
SCOTTSDALE, Ariz., Sept. 10, 2025 /PRNewswire/ -- Imaging Endpoints (IE), the global leader in Imaging CRO technologies and services for oncology trials, announced the filing of a provisional patent application for its revolutionary AI enhanced Imaging Review Charter (IRC) system. This innovative...
2025-09-10 21:00
1210
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
BEIJING, Sept. 10, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB, "LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious ...
2025-09-10 20:10
2373
Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond
Insight Partners leads; seven major U.S. health systems join. Funding accelerates the global rollout of Optain's advanced robotic retinal imaging, AI, and teleophthalmology platform. NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Optain Health, a healthcare technology company applying artificial intel...
2025-09-10 20:00
2025
New Public Perception Survey Highlights Fragmented Cancer Care Pathway in the Philippines; Optimism About Digital Innovations
* YouGov survey finds strong belief in value of early detection (76%) but low screening uptake (13%) * Confidence in coordinated care (34%) and in 'one-stop' care (36%) among the lowest inSoutheast Asia * Strongest regional demand for advanced technology in follow-up care and recurrence det...
2025-09-10 14:00
1476
New Public Perception Survey Highlights Fragmented Cancer Care Pathway in Thailand; Optimism About Digital Innovations
* YouGov survey finds strong belief in value of early detection (88%) but under half screened (40%) * 84% of respondents aware post-treatment care exists, 55% lack understanding of what it involves * Findings show confidence in "one-stop" cancer services and cautious optimism for digital in...
2025-09-10 11:39
2231
New Public Perception Survey Highlights Fragmented Cancer Care Pathway in Indonesia; Optimism About Digital Innovations
* YouGov survey finds belief in value of early detection (65%) but very low screening uptake (8%) * 76% of respondents aware post-treatment care exists, 58% lack understanding of what it involves * Confidence in coordinated care (39%) and in 'one-stop' care (31%) among lowest inSoutheast As...
2025-09-10 11:24
2298
ImmVira Announces First-in-Human Data of Engineered Exosome MVR-EX105 for Fat Reduction and Muscle Preservation by Topical Application at 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders
SUZHOU, China, Sept. 9, 2025 /PRNewswire/ -- ImmVira Group ("ImmVira" or the "Company") recently announced that its lead engineered exosome candidate, MVR-EX105 ("EX105") is featured in a poster presentation at the 2025 Annual Congress of the International Federation for the Surgery of Obesity an...
2025-09-10 10:49
1318
Cadonilimab(PD-1/CTLA-4) plus Pulocimab (VEGFR-2) Combination Therapy Shows Promising Results in IO-Resistant Non-Small Cell Lung Cancer in Oral Presentation at the 2025 WCLC
HONG KONG, Sept. 9, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that data from a Phase Ib/II clinical study evaluating the combination of cadonilimab and pulocimab (an anti-VEGFR-2 antibody) in patients with immunotherapy (IO)-resistant NSCLC were presented in a Mini Oral session at the ...
2025-09-10 10:40
1334
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation ...
2025-09-10 07:01
1634
iRegene Therapeutics Secures Series B+ Financing Following FDA Fast Track Designation for its Flagship Product NouvNeu001
CHENGDU, China, Sept. 9, 2025 /PRNewswire/ -- iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, announced on September 4th the successful completion of its Series B+ financing round, co-led by Nort...
2025-09-09 21:00
1439
Metabolon Partners with China Kadoorie Biobank to Advance Precision Health
The landmark multiomics study will examine how lifestyle, environmental,
socioeconomic, and genetic factors play a significant role in shaping common
diseases
MORRISVILLE, N.C., Sept. 9, 2025 /PRNewswire/ -- Metabolon
2025-09-09 21:00
1579
XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 c...
2025-09-09 20:42
2803
Dizal Showcases Robust Portfolio of Lung Cancer Studies at 2025 WCLC
SHANGHAI, Sept. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced the presentation of new findings on its leading assets, ZEGFROVY® (sunvozertinib) and golidocitinib, in...
2025-09-09 18:00
1429
WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry
* End-to-end Green CRDMO solutions to enable global clients for broader positive impact * Span from biologics research, development, manufacturing, and overall operations * Integration with lean management and digitalization for continuous excellence * A comprehensive ecosystem featuring ...
2025-09-09 18:00
2980
LISCure BioSciences Secures World's First FDA NDI notification for Hair Health Probiotic Mobiome®
SEOUL, South Korea, Sept. 9, 2025 /PRNewswire/ -- LISCure BioSciences ("LISCure") today announced thatMobiome®, its proprietary hair health probiotic, has receivedNew Dietary Ingredient (NDI) Notification from the U.S. Food and Drug Administration (FDA) —the first such recognition worldwide for ...
2025-09-09 13:41
1543
Elevating Healthcare Innovation: ICP DAS-BMP Brings Advanced TPU Portfolio at Medtec China 2025
HSINCHU, Sept. 9, 2025 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), a Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is pleased to announce its participation in Medtec China 2025, to be held fromSeptember 24 to 26 at the Shanghai World Expo Exhibit...
2025-09-09 09:45
2579
Sirtex Receives Expanded CE Mark Approval for SIR-Spheres® Y-90 Resin Microspheres
Broadened indication increases access to liver cancer treatment across Europe and CE-marked territories. WOBURN, Mass., Sept. 8, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of minimally invasive interventional oncology solutions, today announced that it has received an...
2025-09-08 21:00
1346
Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London
PISCATAWAY, N.J., Sept. 8, 2025 /PRNewswire/ -- Cell and gene therapies (CGT) are advancing rapidly and are reshaping the future of medicine. From CRISPR-based genome editing to new applications of in vivo and ex vivo cell therapies, scientific breakthroughs are increasingly moving from the labor...
2025-09-08 20:49
1347
SpaceGut's Precision AI System for Gut Testing Achieves Up to 87% Improvement in Irritable Bowel Syndrome Management
KUALA LUMPUR, Malaysia, Sept. 8, 2025 /PRNewswire/ -- SpaceGut
2025-09-08 20:37
1981
Week's Top Stories
Most Reposted
Visa partners with Laufey to spread the magic of travel in Asia Pacific; to be Official Payment Partner for Laufey: A Matter of Time Tour
[Picked up by 309 media titles]
2026-03-04 12:35
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 290 media titles]
2026-03-02 09:00
Klook's Spring Readiness Index shows how Asia's travelers are preparing for spring travel across Japan, South Korea, and Mainland China
[Picked up by 290 media titles]
2026-03-03 15:49
COL and NASDAQ-Listed BeLive Holdings Unveil World's First "Microdrama in a Box" in Headline Hong Kong FILMART 2026 Launch
[Picked up by 287 media titles]
2026-03-05 17:14
